Finally, our data reconcile conflicting previous evidence by demonstrating improved survival in patients with YOPC compared with patients with AOPC, which may not only reflect the reduced prevalence of the virulent oncogenic drivers KRAS, SMAD4, and CDKN2A in tumor genomes of YOPC patients but also be driven by the significantly longer survival of YOPC-KRASWT versus AOPC-KRASWT patients. This evidence concerns the gene KRAS and neoplasm.